188 related articles for article (PubMed ID: 20332708)
1. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center.
Nikolaou A; Thomas D; Kampanellou C; Alexandraki K; Andersson LG; Sundin A; Kaltsas G
J Endocrinol Invest; 2010 Dec; 33(11):794-9. PubMed ID: 20332708
[TBL] [Abstract][Full Text] [Related]
2. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors.
Orlefors H; Sundin A; Ahlström H; Bjurling P; Bergström M; Lilja A; Långström B; Oberg K; Eriksson B
J Clin Oncol; 1998 Jul; 16(7):2534-41. PubMed ID: 9667275
[TBL] [Abstract][Full Text] [Related]
4. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
Orlefors H; Sundin A; Garske U; Juhlin C; Oberg K; Skogseid B; Langstrom B; Bergstrom M; Eriksson B
J Clin Endocrinol Metab; 2005 Jun; 90(6):3392-400. PubMed ID: 15755858
[TBL] [Abstract][Full Text] [Related]
5. ECTOPIC CUSHING SYNDROME: A 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER IN SOUTHERN INDIA.
Sathyakumar S; Paul TV; Asha HS; Gnanamuthu BR; Paul MJ; Abraham DT; Rajaratnam S; Thomas N
Endocr Pract; 2017 Aug; 23(8):907-914. PubMed ID: 28614007
[TBL] [Abstract][Full Text] [Related]
6. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography.
Orlefors H; Sundin A; Lu L; Oberg K; Långström B; Eriksson B; Bergström M
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):60-5. PubMed ID: 16184369
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
Eriksson B; Bergström M; Lilja A; Ahlström H; Långström B; Oberg K
Acta Oncol; 1993; 32(2):189-96. PubMed ID: 7686763
[TBL] [Abstract][Full Text] [Related]
8. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors.
Carlbom L; Caballero-Corbalán J; Granberg D; Sörensen J; Eriksson B; Ahlström H
Ups J Med Sci; 2017 Mar; 122(1):43-50. PubMed ID: 27894208
[TBL] [Abstract][Full Text] [Related]
9. 11C-5-hydroxytryptophan positron emission tomography after radiofrequency ablation of neuroendocrine tumor liver metastases.
Norlén O; Nilsson A; Krause J; Stålberg P; Hellman P; Sundin A
Nucl Med Biol; 2012 Aug; 39(6):883-90. PubMed ID: 22381780
[TBL] [Abstract][Full Text] [Related]
10. The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors.
Xu H; Zhang M; Zhai G; Zhang M; Ning G; Li B
Endocrine; 2009 Dec; 36(3):385-91. PubMed ID: 19806477
[TBL] [Abstract][Full Text] [Related]
11. PET in the diagnosis of neuroendocrine tumors.
Sundin A; Eriksson B; Bergström M; Långström B; Oberg K; Orlefors H
Ann N Y Acad Sci; 2004 Apr; 1014():246-57. PubMed ID: 15153441
[TBL] [Abstract][Full Text] [Related]
12. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography.
Sundin A; Eriksson B; Bergström M; Bjurling P; Lindner KJ; Oberg K; Långström B
Nucl Med Biol; 2000 Jan; 27(1):33-41. PubMed ID: 10755643
[TBL] [Abstract][Full Text] [Related]
14. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
[TBL] [Abstract][Full Text] [Related]
15. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
[TBL] [Abstract][Full Text] [Related]
16. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
[TBL] [Abstract][Full Text] [Related]
17. Use of radioguided surgery with [111In]-pentetreotide in the management of an ACTH-secreting bronchial carcinoid causing ectopic Cushing's syndrome.
Grossrubatscher E; Vignati F; Dalino P; Possa M; Belloni PA; Vanzulli A; Bramerio M; Marocchi A; Rossetti O; Zurleni F; Loli P
J Endocrinol Invest; 2005 Jan; 28(1):72-8. PubMed ID: 15816375
[TBL] [Abstract][Full Text] [Related]
18. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies.
Eriksson B; Bergström M; Orlefors H; Sundin A; Oberg K; Långström B
Q J Nucl Med; 2000 Mar; 44(1):68-76. PubMed ID: 10932603
[TBL] [Abstract][Full Text] [Related]
19. [Gastrointestinal carcinoid tumors: a multi-technique diagnostic approach].
Mathonnet M
J Chir (Paris); 2007; 144(4):287-92. PubMed ID: 17925731
[TBL] [Abstract][Full Text] [Related]
20. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
